Two years after dismissing Broad Institute’s appeal against revocation of a CRISPR patent, the EPO will revisit questions on examination and validity of priority claims. Sheena Linehan of Potter Clarkson asks why US and European practice has again collided.
This article was originally published by Managing IP and can be viewed here.
